Skip to main content
ConductScienceScienceDex

Marco Ruella

NIH Rank #1526
Unclaimed recordClaim profile
  • R01 Holder
  • Top 10% Funded
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 12681981Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Internal Medicine
  • Pathology

NIH Funding · FY2025

Linked Award Amount
$4.8M
Full award amounts, FY2025
Award Records
3
Records listing this PI
Award-Linked Rank
#1,526
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Marco Ruella. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2025 award records by amount

NIH award records listing Marco Ruella as a PI. Multi-PI records show the full award amount for context.

  • 1R01FD008168-01A1R01
    CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T cell non-Hodgkin lymphoma (NHL): a first-in-human phase I clinical trial
    University of Pennsylvania
    $3.4M
    award amount
  • 1R01HL178849-01R01
    Selective B Cell Depletion Using Engineered T Cells As A Curative Treatment For Acquired Thrombotic Thrombocytopenic Purpura
    University of Pennsylvania
    $810.9K
    award amount
  • 5R37CA262362-04R37
    MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER
    University of Pennsylvania
    $527.5K
    award amount

Award organization

Organizations that administered FY2025 awards listing Marco Ruella as a PI.

FY2025 award administered by University of Pennsylvania (PA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    University of Pennsylvania
  2. 2024
    $500K Cumulative Funding
  3. 2025
    $1M Cumulative Funding
  4. 2025
    $2M Cumulative Funding
  5. 2025
    $5M Cumulative Funding
  6. 2025
    Entered Top 50% Nationally
    Ranked #1526
  7. 2025
    Entered Top 25% Nationally
    Ranked #1526
  8. 2025
    Entered Top 10% Nationally
    Ranked #1526
  9. 2025
    R01 Grant Holder

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Marco Ruella.

Vijay Bhoj
University of Pennsylvania
2
shared awards
Stefan Klaus Barta
University of Pennsylvania
1
shared award
Wendy Beguelin
University of Pennsylvania
1
shared award

Explore further

Find collaborators for Marco Ruella

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →